Halozyme Therapeutics, Inc. (HALO) 2012年年度报告「NASDAQ」.pdf

1、 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington,D.C.20549 FORM 10-K For the fiscal year ended December 31,2012 OR Commission File Number:001-32335 Halozyme Therapeutics,Inc.(Exact name of registrant as specified in its charter)(858)794-8889 (Registrants Telephone Number,Including Area C

2、ode)Securities registered under Section 12(b)of the Act:Securities registered under Section 12(g)of the Act:None Indicate by check mark if the registrant is a well-known seasoned issuer,as defined in Rule 405 of the Securities Act.Yes?No Indicate by check mark if the registrant is not required to fi

3、le reports pursuant to Section 13 or 15(d)of the Act.?Yes No Indicate by check mark whether the registrant(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of 1934 during the preceding 12 months(or for such shorter period that the registrant was requi

4、red to file such reports),and(2)has been subject to such filing requirements for the past 90 days.Yes?No Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site,if any,every Interactive Data File required to be submitted and posted pursuant to

5、Rule 405 of Regulation S-T(232.405 of this chapter)during the preceding 12 months(or for such shorter period that the registrant was required to submit and post such files).Yes?No Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein

6、,and will not be contained,to the best of registrants knowledge,in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.Indicate by check mark whether the registrant is a large accelerated filer,an accelerated filer,a n